Attovia Therapeutics, Inc. · NASDAQ:ATTO
Walsh Colin bought 585,000 and sold 105,607 Attovia Therapeutics, Inc. shares (Form 4/A)
Traded Aug 5 to Aug 6, 2026 · Filed Aug 28, 2026
From Aug 5 to Aug 6, 2026, Walsh Colin (Director) bought 585,000 and sold 105,607 Attovia Therapeutics, Inc. shares, leaving 3,020,632 shares. Filed Aug 28, 2026 (Form 4/A).
- Bought
- 585,000 shares (US$10.3M at an average US$17.58)
- Sold
- 105,607 shares (US$2.25M at an average US$21.28)
- Holding after
- 3,020,632 shares (held indirectly)
- Trading plan
- No
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Common Stock | Buy | 85,000 | US$21.00 | 85,000 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 988 | US$22.03 | 84,012 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 447 | US$21.87 | 83,565 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 1,332 | US$22.03 | 82,233 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 200 | US$22.05 | 82,033 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 1,556 | US$22.06 | 80,477 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 3,402 | US$22.02 | 77,075 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 200 | US$22.10 | 76,875 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 480 | US$21.55 | 76,395 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 100 | US$22.11 | 76,295 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 753 | US$21.97 | 75,542 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 672 | US$22.02 | 74,870 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 6,970 | US$22.03 | 67,900 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 400 | US$22.02 | 67,500 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 1,180 | US$21.84 | 66,320 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 1,040 | US$22.05 | 65,280 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 300 | US$20.84 | 64,980 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 443 | US$21.78 | 64,537 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 700 | US$22.07 | 63,637 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 1,163 | US$22.19 | 62,474 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 100 | US$21.99 | 62,374 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 6,763 | US$21.61 | 55,611 | Indirect |
| Aug 5, 2026 | Common Stock | Sale | 76,418 | US$21.04 | 0 | Indirect |
| Aug 6, 2026 | Common Stock | Conversion | 1,957,134 | 2,042,134 | Indirect | |
| Aug 6, 2026 | Common Stock | Conversion | 478,498 | 2,520,632 | Indirect | |
| Aug 6, 2026 | Common Stock | Buy | 500,000 | US$17.00 | 3,020,632 | Indirect |
Source
Related
- Attovia Therapeutics, Inc.
- Walsh Colin
- Attovia Therapeutics, Inc. shareholders
- Form 4/A · Goldman Sachs Asset Management, L.P. · Aug 28, 2026
- Form 4 · Goldman Sachs & Co. LLC · Aug 13, 2026
- Schedule 13G · Deep Track Capital, LP · Aug 12, 2026
- Schedule 13D · Frazier Life Sciences XI, L.P. · Aug 11, 2026
- Form 4 · venBio Global Strategic Fund IV, L.P. · Aug 10, 2026